IBA Worldwide
IBA develops, manufactures and supports medical devices and software solutions for cancer treatment by proton beam therapy.
Launch date
Employees
Market cap
$431m
Enterprise valuation
$431m (Public information from Sep 2024)
Share price
€13.7 IBAB.BR
Ottignies-Louvain-la-Neuve Walloon Brabant (HQ)
Financials
Estimates*
EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 283m | 312m | 313m | 361m | 429m | 454m | 512m |
% growth | 36 % | 10 % | - | 15 % | 19 % | 6 % | 13 % |
EBITDA | 14.7m | 46.7m | 25.9m | 18.9m | 16.5m | - | - |
% EBITDA margin | 5 % | 15 % | 8 % | 5 % | 4 % | - | - |
Profit | 7.6m | 31.9m | 3.9m | 6.1m | (9.1m) | - | - |
% profit margin | 3 % | 10 % | 1 % | 2 % | (2 %) | - | - |
R&D budget | 31.1m | 33.1m | 34.0m | 41.8m | 47.9m | - | - |
R&D % of revenue | 11 % | 11 % | 11 % | 12 % | 11 % | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
Total Funding | - |
Related Content
Recent News about IBA Worldwide
EditInvestments by IBA Worldwide
EditACQUISITION by IBA Worldwide Feb 2024
ACQUISITION by IBA Worldwide May 2022